Cargill and Eagle Genomics, a life sciences and microbiome knowledge discovery company, announced that they have signed a multiyear platform agreement to enable the digital transformation of microbiome and life sciences research and development (R&D) across Cargill's global locations.

The deployment of the Eagle Genomics e[datascientist] platform will initially enable Cargill's Health Technologies business to organize and synthesize additional insights from microbiome data amassed by the company over the past decade.

"By revealing relationships between microbiome data entities and relevant multi-omics data, the platform will further enable Cargill to advance our understanding of the complex association between the microbiome and digestive and immune health in humans and animals," Cargill Health Technologies marketing director Mike Johnson said.

"Healthy animals, healthy people and a healthy planet are all interconnected," he explained. "With the advanced knowledge and insights we anticipate generating from our microbiome data, the e[datascientist] will allow us to effectively build on our existing suite of health solutions and bring more relevant products to market in this exciting area of functional food."

With the capabilities to manage, explore and interpret life sciences data beyond the microbiome, the Eagle Genomics platform will ultimately allow Cargill to digitally reinvent its biological research activities to bring innovative products to customers faster.

By focusing particularly on the microbiome, Eagle Genomics said it is accelerating advances in the fields of sustainable agriculture and functional food. The Eagle Genomics e[datascientist] platform applies artificial intelligence, a unique data valuation engine and pioneering visualization to navigate and reveal novel relationships between data entities at the microbiomical scale.

"We are delighted to be enabling Cargill to explore microbiome data for food and digestive health -- an area we believe will be transformed by microbiome discovery over the next decade,” Eagle Genomics chief executive officer Anthony Finbow said. “We look forward to a future of industry-disrupting food and nutraceutical products for humans and animals, informed by our platform."